Recently, the FDA issued a nuvaring label change. Apparently, a nuvaring label change was approved by the FDA Center for Drug Evaluation and Research (CDER) on October 2013. The nuvaring label change was related to Thromboembolic Disorders and Other Vascular Problems. In particular, the nuvaring label change stated the following:
- Stop NuvaRing use if an arterial thrombotic or venous thromboembolic event (VTE) occurs. Stop NuvaRing use if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately. [See Adverse Reactions (6).]
- If feasible, stop NuvaRing at least four weeks before and through two weeks after major surgery or other surgeries known to have an elevated risk of thromboembolism, and during and following prolonged immobilization.
A number of lawsuits have been filed alleging the companies involved concealed the health risks associated with using the NuvaRing. Some of the potential problems that may be caused by NuvaRing, include:
If you have been injured by your use of Nuvaring, and would like your case evaluated or need help in filing a nuvaring lawsuit, please contact us.
At the Gooch Law Firm, we pride ourselves on providing our clients reliable representation for even the most challenging cases. If you were hospitalized after experiencing complications related to the NuvaRing, contact our office at 1.844.329.5955.
WE ARE HERE TO HELP YOU PROTECT YOUR LEGAL RIGHTS